De novo design of lipopeptide-based fusion inhibitor as potential broad-spectrum antiviral agent

The recent surge in emerging viral infections warrants the need to design broad-spectrum antivirals. We aimed to develop a lead molecule that targets the membrane to block fusion, an obligate step of enveloped virus infection. The approach is based on the Coronin-1 protein of Mycobacterium, which presumably inhibits the phagosome-lysosome fusion, and a unique Trp-Asp (WD) sequence is placed at the distorted -meander motif. We have designed a WD-based branched lipopeptide that supports C=OHN hydrogen-bonding, the tryptophan-tryptophan - stacking, and the intermolecular H-bonding between COO and CO2H groups. These cooperative interactions are expected to create a -sheet-like supramolecular assembly at the membrane surface, which increases the interfacial order, and decreases the water penetration. Myr-D(WD)2 was shown to block artificial membrane fusion completely. We demonstrated that the Myr-D(WD)2 supramolecular organization can restrict the infection from H1N1, H9N2, murine coronavirus, and human coronavirus (HCoV-OC43). Together, the present study provided an evidence-based broad-spectrum antiviral potential of a designed small lipopeptide.